GlassScriptPhysician profile
Mrunal C Patel
NPI 1528000734
$2,252.77
in general payments reported to CMS, 2019-2025
21 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $196 · 2021: $480 · 2022: $273 · 2023: $394 · 2024: $197 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.73 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.65 | 2020-2025 | |
| Gilead Sciences, INC. | $270.57 | 2019-2025 | |
| Pfizer INC. | $268.38 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $246.39 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $240.22 | 2024-2025 | Ibsrela |
| Allergan, INC. | $109.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.92 | 2020-2023 | Xifaxan |
| Janssen Biotech, INC. | $61.18 | 2021-2022 | |
| Celgene Corporation | $59.32 | 2021-2023 | Zeposia |
| Olympus America INC. | $55.04 | 2022 | |
| Boston Scientific Corporation | $54.79 | 2020 | |
| Genzyme Corporation | $47.83 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $41.85 | 2024-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $37.73 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $21.30 | 2024 | Resmetirom |
| Organon LLC | $18.30 | 2022 | |
| Vericel Corporation | $17.17 | 2025 | Maci |
| Ethicon US, LLC | $16.92 | 2021 | |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Medtronic, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrunal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.